Interestingly, inhibiting ACLY reduced the intracellular citrate level and cell viability of breast cancer cell lines more effectively than inhibiting citrate transport protein (CTP) [206], but whether inhibiting both CTP and ACLY produces a synergistic antitumour effect is underexamined. Here, SLC25A1 is linked to breast cancer.